5 Basel Street, P.O. Box 3190 Petach Tikva 49131 Israel
———————————————————————————————————
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: [x] Form 20-F [ ] Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: [ ] Yes [x] No
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Teva Pharmaceutical Industries Ltd.
Date: 12/17/2012
By:
Eyal Desheh
Name:
Eyal Desheh
Title:
Chief Financial Officer
EXHIBIT INDEX
Exhibit No.
Description
99.1
Teva Enters Agreement with Handok to Establish Business Venture with Significant Presence in Korean Pharmaceutical Market
Bet you've never seen portfolio analytics like these.
